{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:14:08Z","timestamp":1773976448561,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100010891","name":"Portola Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s11239-019-01943-5","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T06:03:26Z","timestamp":1567749806000},"page":"214-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial"],"prefix":"10.1007","volume":"49","author":[{"given":"Walter","family":"Ageno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan K.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Hull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"1943_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1160\/TH17-06-0403","volume":"118","author":"M Blondon","year":"2018","unstructured":"Blondon M, Spirk D, Kucher N et al (2018) Comparative performance of clinical risk assessment models for hospital-acquired venous thromboembolism in medical patients. Thromb Haemost 118:82\u201389","journal-title":"Thromb Haemost"},{"issue":"2 Suppl.","key":"1943_CR2","doi-asserted-by":"publisher","first-page":"e195S","DOI":"10.1378\/chest.11-2296","volume":"141","author":"SR Kahn","year":"2012","unstructured":"Kahn SR, Lim W, Dunn AS et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl.):e195S\u2013e226S","journal-title":"Chest"},{"key":"1943_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.amjmed.2013.09.015","volume":"127","author":"M Carrier","year":"2014","unstructured":"Carrier M, Khorana AA, Moretto P et al (2014) Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 127:82\u201386","journal-title":"Am J Med"},{"key":"1943_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1056\/NEJMoa1601747","volume":"375","author":"AT Cohen","year":"2016","unstructured":"Cohen AT, Harrington RA, Goldhaber SZ et al (2016) Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 375:534\u2013544","journal-title":"N Engl J Med"},{"key":"1943_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ahj.2013.11.006","volume":"167","author":"AT Cohen","year":"2014","unstructured":"Cohen AT, Harrington RA, Goldhaber SZ et al (2014) The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study. Am Heart J 167:335\u2013341","journal-title":"Am Heart J"},{"key":"1943_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 3:692\u2013694","journal-title":"J Thromb Haemost"},{"key":"1943_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1378\/chest.09-3081","volume":"139","author":"H Decousus","year":"2011","unstructured":"Decousus H, Tapson VF, Bergmann J-F et al (2011) Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 139:69\u201379","journal-title":"Chest"},{"key":"1943_CR8","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","volume":"8","author":"S Barbar","year":"2010","unstructured":"Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8:2450\u20132457","journal-title":"J Thromb Haemost"},{"key":"1943_CR9","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1378\/chest.10-1944","volume":"140","author":"AC Spyropoulos","year":"2011","unstructured":"Spyropoulos AC, Anderson FA, FitzGerald G, IMPROVE Investigators et al (2011) Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140:706\u2013714","journal-title":"Chest"},{"key":"1943_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7326\/0003-4819-153-1-201007060-00004","volume":"153","author":"RD Hull","year":"2010","unstructured":"Hull RD, Schellong SM, Tapson VF, EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study et al (2010) Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 153:8\u201318","journal-title":"Ann Intern Med"},{"key":"1943_CR11","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","volume":"365","author":"SZ Goldhaber","year":"2011","unstructured":"Goldhaber SZ, Leizorovicz A, Kakkar AK, ADOPT Trial Investigators et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167\u20132177","journal-title":"N Engl J Med"},{"key":"1943_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1111096","volume":"368","author":"AT Cohen","year":"2013","unstructured":"Cohen AT, Spiro TE, B\u00fcller HR, MAGELLAN Investigators et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513\u2013523","journal-title":"N Engl J Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01943-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-019-01943-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01943-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T23:12:36Z","timestamp":1599261156000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-019-01943-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1007\/s11239-019-01943-5","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"6 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The APEX study was funded by Portola Pharmaceuticals. Megan K. Yee, Adrian Hernandez, Russell Hull, Samuel Z. Goldhaber, C Michael Gibson, and Alexander T Cohen have received grant support from Portola Pharmaceuticals. In addition, Walter Ageno has received grant support from Bayer and honoraria from Bayer, Boehringer Ingelheim, BMS\/Pfizer, Daiichi Sankyo, Janssen, Portola, Sanofi, Aspen; Renato D. Lopes has received honoraria from Bayer, Boehringer Ingelheim, BMS, Pfizer, Daiichi Sankyo, Portola, Sanofi, Glaxo Smith Kline, Medtronic, Merck; Russell Hull has received honoraria from Sanofi; Adrian Hernandez has received honoraria from BMS, Pfizer, Astra Zeneca; C. Michael Gibson has received grants from Angel Medical Corporation, Bayer, CSL Behring, Janssen, Johnson and Johnson and honoraria from Angel Medical Corporation, Bayer, CSL Behring, Janssen, Johnson and Johnson, The Medicines Company, Boston Clinical Research Institute, Cardiovascular Research Foundation, Eli Lilly, Gilead Sciences, Novo Nordisk, Web MD, UpToDate in Cardiovascular Medicine, Amarin Pharma, Amgen, Boehringer Ingelheim, Chiesi, Merck, PharmaMar, Sanofi, Somahlution, St. Francis Hospital, Verreseon Corporation, Boston Scientific, Duke Clinical Research Institute, Impact Bio, Medimmune, Medtelligence, Microport, PERT Consortium; Alexander T Cohen has received grant support from BMS, Daiichi Sankyo, Pfizer and honoraria from BMS, Daiichi Sankyo, Pfizer, ONO.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}}]}}